Bone Targeting Nanoparticles for the Treatment of Osteoporosis

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2024 Feb 19

PMID 38371454

Authors

Caining Wen

Xiao Xu

Yuanmin Zhang

Jiang Xia

Yujie Liang

Limei Xu

Affiliations

Soon will be listed here.

Abstract

Osteoporosis (OP) affects millions of people worldwide, especially postmenopausal women and the elderly. Although current available anti-OP agents can show promise in slowing down bone resorption, most are not specifically delivered to the hard tissue, causing significant toxicity. A bone-targeted nanodrug delivery system can reduce side effects and precisely deliver drug candidates to the bone. This review focuses on the progress of bone-targeted nanoparticles in OP therapy. We enumerate the existing OP medications, types of bone-targeted nanoparticles and categorize pairs of the most common bone-targeting functional groups. Finally, we summarize the potential use of bone-targeted nanoparticles in OP treatment. Ongoing research into the development of targeted ligands and nanocarriers will continue to expand the possibilities of OP-targeted therapies into clinical application.

Citing Articles

Apoptosis and cell cycle arrest of bone marrow cells by green-synthesized silver but not albumin nanoparticles.

Eldabousy E, Habbak L, Hyder A Toxicol Rep. 2025; 14:101960.

PMID: 40026477 PMC: 11872133. DOI: 10.1016/j.toxrep.2025.101960.

Investigating the biology of microRNA links to ALDH1A1 reveals candidates for preclinical testing in acute myeloid leukemia.

Vlahopoulos S, Varisli L, Zoumpourlis P, Spandidos D, Zoumpourlis V Int J Oncol. 2024; 65(6).

PMID: 39513593 PMC: 11575927. DOI: 10.3892/ijo.2024.5703.

Osteoporotic osseointegration: therapeutic hallmarks and engineering strategies.

Chen J, Hao Z, Li H, Wang J, Chen T, Wang Y Theranostics. 2024; 14(10):3859-3899.

PMID: 38994021 PMC: 11234277. DOI: 10.7150/thno.96516.

Lymphoid organ-targeted nanomaterials for immunomodulation of cancer, inflammation, and beyond.

Hsu J, Liu P, Song Y, Song W, Saladin R, Peng Y Chem Soc Rev. 2024; 53(15):7657-7680.

PMID: 38958009 PMC: 11334694. DOI: 10.1039/d4cs00421c.

References

Dadfar S, Roemhild K, Drude N, von Stillfried S, Knuchel R, Kiessling F . Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev. 2019; 138:302-325. PMC: 7115878. DOI: 10.1016/j.addr.2019.01.005. View

Min Y, Caster J, Eblan M, Wang A . Clinical Translation of Nanomedicine. Chem Rev. 2015; 115(19):11147-90. PMC: 4607605. DOI: 10.1021/acs.chemrev.5b00116. View

Li Y, Ye D, Li M, Ma M, Gu N . Adaptive Materials Based on Iron Oxide Nanoparticles for Bone Regeneration. Chemphyschem. 2018; 19(16):1965-1979. DOI: 10.1002/cphc.201701294. View

Viereck V, Grundker C, Blaschke S, Niederkleine B, Siggelkow H, Frosch K . Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab. 2003; 88(9):4206-13. DOI: 10.1210/jc.2002-021877. View

Xu X, Liang Y, Li X, Ouyang K, Wang M, Cao T . Exosome-mediated delivery of kartogenin for chondrogenesis of synovial fluid-derived mesenchymal stem cells and cartilage regeneration. Biomaterials. 2020; 269:120539. DOI: 10.1016/j.biomaterials.2020.120539. View

Gabizon A, Shmeeda H, Barenholz Y . Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003; 42(5):419-36. DOI: 10.2165/00003088-200342050-00002. View

Ways T, Lau W, Khutoryanskiy V . Chitosan and Its Derivatives for Application in Mucoadhesive Drug Delivery Systems. Polymers (Basel). 2019; 10(3). PMC: 6414903. DOI: 10.3390/polym10030267. View

Narayanan D, Anitha A, Jayakumar R, Nair S, Chennazhi K . Synthesis, characterization and preliminary in vitro evaluation of PTH 1-34 loaded chitosan nanoparticles for osteoporosis. J Biomed Nanotechnol. 2012; 8(1):98-106. DOI: 10.1166/jbn.2012.1367. View

Sekido T, Sakura N, Higashi Y, Miya K, Nitta Y, Nomura M . Novel drug delivery system to bone using acidic oligopeptide: pharmacokinetic characteristics and pharmacological potential. J Drug Target. 2001; 9(2):111-21. DOI: 10.3109/10611860108997922. View

10.

Xu X, Iqbal Z, Xu L, Wen C, Duan L, Xia J . Brain-derived extracellular vesicles: Potential diagnostic biomarkers for central nervous system diseases. Psychiatry Clin Neurosci. 2023; 78(2):83-96. DOI: 10.1111/pcn.13610. View

11.

Rodan G, Reszka A . Bisphosphonate mechanism of action. Curr Mol Med. 2002; 2(6):571-7. DOI: 10.2174/1566524023362104. View

12.

Ruggiero S, Mehrotra B, Rosenberg T, Engroff S . Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 2004; 62(5):527-34. DOI: 10.1016/j.joms.2004.02.004. View

13.

Guo J, Wang F, Hu Y, Luo Y, Wei Y, Xu K . Exosome-based bone-targeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases. Cell Rep Med. 2023; 4(1):100881. PMC: 9873828. DOI: 10.1016/j.xcrm.2022.100881. View

14.

Vo T, Kasper F, Mikos A . Strategies for controlled delivery of growth factors and cells for bone regeneration. Adv Drug Deliv Rev. 2012; 64(12):1292-309. PMC: 3358582. DOI: 10.1016/j.addr.2012.01.016. View

15.

Gaba B, Fazil M, Ali A, Baboota S, Sahni J, Ali J . Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration. Drug Deliv. 2014; 22(6):691-700. DOI: 10.3109/10717544.2014.898110. View

16.

Ensrud K, Crandall C . Osteoporosis. Ann Intern Med. 2017; 167(3):ITC17-ITC32. DOI: 10.7326/AITC201708010. View

17.

Khajuria D, Disha C, Vasireddi R, Razdan R, Mahapatra D . Risedronate/zinc-hydroxyapatite based nanomedicine for osteoporosis. Mater Sci Eng C Mater Biol Appl. 2016; 63:78-87. DOI: 10.1016/j.msec.2016.02.062. View

18.

Beekman K, Zwaagstra M, Veldhuis-Vlug A, van Essen H, den Heijer M, Maas M . Ovariectomy increases RANKL protein expression in bone marrow adipocytes of C3H/HeJ mice. Am J Physiol Endocrinol Metab. 2019; 317(6):E1050-E1054. DOI: 10.1152/ajpendo.00142.2019. View

19.

Pandey M, Choudhury H, Gunasegaran T, Nathan S, Md S, Gorain B . Hyaluronic acid-modified betamethasone encapsulated polymeric nanoparticles: fabrication, characterisation, in vitro release kinetics, and dermal targeting. Drug Deliv Transl Res. 2018; 9(2):520-533. DOI: 10.1007/s13346-018-0480-1. View

20.

Odvina C, Zerwekh J, Rao D, Maalouf N, Gottschalk F, Pak C . Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2004; 90(3):1294-301. DOI: 10.1210/jc.2004-0952. View